Brought to you by 
Sarepta gains ex-European license to Lysogene's LYS-SAF302 MPS IIIA gene therapy candidate; LYS-SAF302 License Agreement Terminated
14 Jan 2022
Executive Summary
Sarepta Therapeutics Inc. licensed exclusive worldwide commercialization (except in Europe) and manufacturing rights to Lysogene's LYS-SAF302 gene therapy candidate for the lysosomal storage disorder mucopolysaccharidosis type IIIA (MPS IIIA; also known as Sanfilippo A syndrome).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sarepta gains ex-European license to Lysogene's LYS-SAF302 MPS IIIA gene therapy candidate; LYS-SAF302 License Agreement Terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice